Immunotherapy for the treatment of glioblastoma.
Immunotherapy for the treatment of glioblastoma.
复制标题
DOI：
10.1097/ppo.0b013e3182431a73
复制
发表时间：
2012-01
期刊：
影响因子：
--
通讯作者：
Fadul CE
中科院分区：
文献类型：
--
作者：
Thomas AA;Ernstoff MS;Fadul CE
胶质母细胞瘤是最具侵袭性的原发性脑肿瘤，在相对免疫特权的中枢神经系统中相对免疫抑制的微环境中茁壮成长。尽管有手术、放射治疗和化疗，预后仍然很差。最近免疫疗法在治疗其他癌症方面的成功重新引起了人们对胶质瘤疫苗治疗的兴趣。在本文中，我们概述了各种免疫治疗策略，回顾了最近的临床试验数据，并讨论了胶质母细胞瘤疫苗治疗的未来。
Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.